Ginkgo Bioworks Holdings (DNA) Cash from Investing Activities Growth (3y) (2023 - 2026)

Ginkgo Bioworks Holdings (DNA) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -29.84%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 38.24%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -22.09%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ginkgo Bioworks Holdings 445.24 Mn 301.37 Mn 16.38 Mn 47.23%

Historic Data

Download Data
DateValue
Mar 31, 2026 47.23%
Dec 31, 2025 47.33%
Sep 30, 2025 -16.14%
Jun 30, 2025 -63.33%
Mar 31, 2025 -76.74%
Dec 31, 2024 -72.07%
Sep 30, 2024 30.59%
Jun 30, 2024 -3.90%
Mar 31, 2024 19.30%
Dec 31, 2023 -17.42%